Cancer Biopsy Market Report 2026

Cancer Biopsy Market Overview

• Cancer Biopsy market size has reached to $28.52 billion in 2025 • Expected to grow to $53.38 billion in 2030 at a compound annual growth rate (CAGR) of 13.3% • Growth Driver: Surge In Cancer Cases Expected To Drive Growth In The Cancer Biopsy Market • Market Trend: Advancements In Cancer Diagnostics For Early Detection And Personalized Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Cancer Biopsy Market?

A cancer biopsy is a medical procedure that involves the removal of a small sample of tissue or cells from a suspicious area of the body to determine the presence of cancer or other conditions. This procedure is essential for diagnosing cancer, as imaging tests such as computed tomography (CT) scans or magnetic resonance imaging (MRI) cannot definitively differentiate between cancerous and non-cancerous cells. The main types of cancer biopsies are tissue biopsies, liquid biopsies, and others. Tissue biopsies involve the removal of a small sample of tissue from the body for examination under a microscope. These are used in various applications such as breast cancer, colorectal cancer, cervical cancers, lung cancers, prostate cancers, skin cancers, blood cancers, kidney cancers, and others, and also by various end users such as hospitals, diagnostic laboratories, and others.

What Is The Cancer Biopsy Market Growth Forecast?

The cancer biopsy market size is expected to see rapid growth in the next few years. It will grow to $53.38 billion in 2030 at a compound annual growth rate (CAGR) of 13.3%. The growth in the forecast period can be attributed to increasing demand for precision oncology diagnostics, rising adoption of liquid biopsy testing, expansion of personalized cancer treatment planning, growing investments in molecular diagnostics, increasing focus on early-stage cancer screening. Major trends in the forecast period include increasing adoption of liquid biopsy techniques, rising use of image-guided biopsy procedures, growing integration of molecular pathology testing, expansion of minimally invasive biopsy devices, enhanced focus on early cancer detection.

Global Cancer Biopsy Market Segmentation

1) By Type: Tissue Biopsies, Liquid Biopsies, Other Types 2) By Application: Breast Cancer, Colorectal Cancer, Cervical Cancers, Lung Cancers, Prostate Cancers, Skin Cancers, Blood Cancers, Kidney Cancers, Other Applications 3) By End User: Hospitals, Diagnostic Laboratories, Other End Users Subsegments: 1) By Tissue Biopsies: Core Needle Biopsies, Fine Needle Aspiration (FNA) Biopsies, Incisional Biopsies, Excisional Biopsies 2) By Liquid Biopsies: Circulating Tumor Cell (CTC) Analysis, Circulating Tumor DNA (ctDNA) Testing, Plasma Biomarker Testing 3) By Other Types: Bone Biopsies, Endoscopic Biopsies, Brush Biopsies, Skin Biopsies

What Is The Driver Of The Cancer Biopsy Market?

The increasing prevalence of cancer is expected to propel the growth of the cancer biopsy market going forward. Cancer is a complex group of diseases characterized by the abnormal growth and spread of cells. The increasing prevalence of cancer is due to several factors, such as lifestyle changes and urbanization, environmental pollution, tobacco and alcohol consumption, healthcare access, and awareness. A cancer biopsy is used to diagnose and assess cancer type, stage, and spread by extracting and analyzing tissue or cells from a suspicious area. For instance, in February 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, by 2050, over 35 million new cancer cases were projected, representing a 77% increase compared to the estimated 20 million cases in 2022. Therefore, the increasing prevalence of cancer drives the cancer biopsy industry.

Key Players In The Global Cancer Biopsy Market

Major companies operating in the cancer biopsy market are Thermo Fisher Scientific Inc., Danaher Corporation, Becton Dickinson and Company, Roche Diagnostics GmbH, Hologic Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Exact Sciences Corporation, Myriad Genetics Inc., Guardant Health Inc., Veracyte Inc., GRAIL Inc., Freenome Holdings Inc., Biodesix Inc., Chronix Biomedical Inc., Biocept Inc., Personal Genome Diagnostics Inc., Agena Bioscience Inc., Oncimmune Holdings plc, Exosome Diagnostics Inc., Epigenomics AG, Genesystems Inc., Lucence Diagnostics Pte. Ltd., ANGLE plc

Global Cancer Biopsy Market Trends and Insights

Major companies operating in the cancer biopsy market are developing liquid biopsy techniques to enable non-invasive, early detection and monitoring of cancer, improve patient outcomes, and allow for more personalized treatment approaches. Liquid biopsy is an advanced, non-invasive diagnostic technique that detects and analyzes genetic material from a blood sample, such as circulating tumor DNA (ctDNA), RNA, exosomes, and other biomarkers. For instance, in May 2023, Labcorp, a US-based company specializing in the manufacturing of cancer biopsies, launched Labcorp Plasma Focus, a plasma-focused liquid biopsy to detect cancer-related biomarkers. The Plasma Focus test analyzes circulating cell-free DNA (cfDNA) released from tumor cells into the bloodstream and can construct a genomic profile of the patient's tumor, identifying mutations across 33 genes associated with various cancers, including non-small cell lung cancer, colorectal cancer, breast cancer, esophageal cancer, and melanoma.

What Are Latest Mergers And Acquisitions In The Cancer Biopsy Market?

In June 2023, Quest Diagnostics, a US-based provider of diagnostic information services, acquired Haystack Oncology for up to $450 million. The acquisition seeks to strengthen its expertise in cancer diagnostics, with a focus on minimal residual disease (MRD) detection. Haystack Oncology is a US-based company specializing in liquid biopsy technology for cancer detection.

Regional Outlook

North America was the largest region in the cancer biopsy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Cancer Biopsy Market?

The cancer biopsy market consists of sales of biopsy needles, biopsy guns, and biopsy punches. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Cancer Biopsy Market Report 2026?

The cancer biopsy market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the cancer biopsy industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.